Purpose: The purpose of this paper is to study the absorptive capacity types in the knowledge management literature and aims to understand how companies can strength their contexts of cooperation in order to innovate.Design/methodology/approach: A balanced panel of 1,220 firms that respond to the Survey of Business Strategies for a three-year period was used, which represents a total of 3,660 observations.  Findings: The justification of absorptive capacity typology for an innovation efficiency process. The influence of the potential and realized absorptive capacity on new products is significant and causes effects on internal research and development in diverse way. The impact of the joint ventures, suppliers’ cooperation and customers’ cooperation are significant on absorptive capacity.Research limitations/implications: It would be interesting to extend the research to another innovation metrics as new organizational methods, new processes, new designs or new methods in the use of sales channels.Practical implications: The agreement of cooperation activities constitutes an important decision for the firm’s innovation. Companies must be conscious that while suppliers and customers’ cooperation are relevant cooperation actions to increase the internal research and development, joint ventures and customers’ cooperation are significant to the growth of the new products.Social implications: The types of absorptive capacity and internal research and development serve as mediating mechanisms between cooperative activities and innovative performance.Originality/value: This paper advances the literature on absorptive capacity by showing how firms use their positions of technological vigilance and management to form their capabilities, and subsequently, to enhance innovation outcomes. This study considers it is necessary to analyze the typology of the absorptive capacity that can allow managers to understand an innovation efficiency process in the cooperation context and make better decisions. The confluence of cooperation activities, absorptive capacity and organizational objectives in internal research and development obtain higher innovative results.

No abstract

No abstract

No abstract

CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low‐prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15‐year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research.